CTS: Sequential Erlotinib Therapy Influences Progression-Free Survival in NSCLC

November 19, 2008

CHICAGO (MedPage Today) -- Progression-free survival among non-small-cell lung cancer patients improved if they were treated with erlotinib (Tarceva) in a sequential treatment strategy as opposed to use of the tyrosine kinase inhibitor as a second-line therapy.

Written by MedPageToday.com - medical news plus CME for physicians · Filed Under Medical News